Cite
HARVARD Citation
Ebata, S. et al. (2022). Safety and efficacy of rituximab in systemic sclerosis (DESIRES): open-label extension of a double-blind, investigators-initiated, randomised, placebo-controlled trial. Lancet. pp. e546-e555. [Online].